Where Does the USPTO Go after Tafas/GSK v. Dudas?

Article co-written by Yuri Levin-Schwartz, Ph.D., a law clerk at MBHB.

FTC warns pharma companies it means business with its Orange Book listing policy

AI News Roundup – Export controls on AI models, $3.3 billion AI datacenter, AI-created content labels, and more

© 2024 McDonnell Boehnen Hulbert & Berghoff LLP snippets is a trademark of McDonnell Boehnen Hulbert & Berghoff LLP. All rights reserved. The information contained in this newsletter reflects the understanding and opinions of the author(s) and is provided to you for informational purposes only. It is not intended to and does not represent legal advice. MBHB LLP does not intend to create an attorney–client relationship by providing this information to you. The information in this publication is not a substitute for obtaining legal advice from an attorney licensed in your particular state. snippets may be considered attorney advertising in some states.

Where Does the USPTO Go after Tafas/GSK v. Dudas?

Practices & Technologies

FTC warns pharma companies it means business with its Orange Book listing policy

AI News Roundup – Export controls on AI models, $3.3 billion AI datacenter, AI-created content labels, and more

Donald L. Zuhn

Private: Benjamin R. Huber